Day 1 Stream 1: Innovation in Genome and Cell Based Drug Discovery

- New for 2018!
  - Next Generation Drug Discovery
  - High Dimensional Phenotypic Signatures
  - Artificial Intelligence Driven Target Identification
  - Phenomics in Drug Discovery
  - New Strategies and Tools for High Content Technologies
  - Novel Approaches for Phenotypic Screening
  - High Content Screening & Data Management

Day 1 Stream 2: Successful Phenotypic Drug Discovery and Other High Content Screening Tools

- New for 2018!
  - Natural Products as Templates For Drug Discovery
  - Drug Target Kinetics in Drug Discovery
  - Network Driven Approaches for Drug Discovery
  - Novel Therapies for Cancer and Emerging Targets
  - Kinase Inhibitors: Cancer Immunotherapy Discovery, Autoimmune and Inflammatory Diseases, CNS and Neurodegenerative Disorders
  - Cancer metabolism / Cancer Metabolism Targets - Including Anti-Cachexia Strategies
  - Novel approaches for protein misfolding diseases
  - T-Cells as platforms for immuno-therapy

Day 2 Stream 2:

**PART 1: Lead Identification and Discovery ADMET**

- Lead optimisation for drug discovery
- ADMET Strategies in Drug Discovery
- Technologies to support safety optimization

**PART 2: Innovation in Genome and Cell Based Drug Discovery, Screening, Imaging & Target Discovery**

- New for 2018! Techniques and Tools for Novel Pathway and Target Discovery
- Novel Applications in RNAi Screening
- 3D Cell Culture-Based approaches
- siRNA Screening for Drug Target Identification
- Gene Editing for Drug Discovery
- CRISPR for Disease Modeling and Target Discovery
- Novel Platforms for Gene Based Drug Discovery

Discovery Chemistry & Drug Design Congress

**Day 1 Stream 3:**

**PART 1: Discovery Chemistry, Medicinal and Computational Chemistry**

- New for 2018! Data Visualisation and Drug Design
- Computational Chemistry Approaches and Drug Discovery
- From Classical Computational Chemistry to Data Analysis and Data Integration
- Medicinal Chemistry for Oncology

**PART 2: Drug Discovery Enabled Technologies; DNA Encoded Libraries**

- New for 2018!
  - DNA Encoded Libraries – from Binding to Functional Activity
  - HT Identification Technology
  - DNA Encoded Libraries
  - DNA Encoded Library Screening
  - Small Molecule Drug Discovery

**Day 2 Stream 3:**

**Medicinal Chemistry and Drug Design: Novel Approaches**

- New for 2018!
  - Protein-Protein Interactions - inhibition, modulation and stabilization
  - 3D Hinge Binding Fragments and Hit Finding
  - Structure Based Drug Design of Kinase Inhibitors
  - Fragment-Based Drug Discovery
  - Peptide Discovery and Development
  - Computational Based Drug Design
  - CNS – Interfacing Chemistry and Biology to Advance Neuroscience Drug Discovery
  - Metabolic and Inflammation – Medicinal Chemistry, Metabolic Profiling and Drug Target Discovery

Benefits to Attending

- Discuss new strategies for efficiency and innovation with leading experts in the field. 2017 attendees include: Chief Scientific Officer Global Neurodegeneration, Eli Lilly; Vice President Discovery Chemistry, MSD; Vice President Research, Amgen; Vice President, Head of Alliance Management, AbbVie

- Hear about new modalities in drug discovery. This congress will look at the future of drug discovery in new modalities as well as new modalities for challenging drug targets

- Discover the latest updates in drug discovery enabled technologies. Key areas to be explored include, 3D modelling, phenotypic screening and CRISPR for disease modelling and drug discovery

- Join in high-level discussions on novel drug target discovery for immune-therapy, autoimmune diseases and oncology. New for 2018 this congress will be looking at natural products and drug-target kinetics in drug discovery

- Benefit from key insights into medicinal chemistry strategies, computational chemistry, and novel approaches to drug design through two specialised discovery and computational chemistry streams. New for 2018 this congress will take a deep dive into DNA encoded libraries focusing on the reach and scope of this tool

- Unparalleled networking opportunities. The two-day congress format combines dedicated networking breaks, pre-organised 1-2-1 meetings and our popular drinks reception. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion

- Co-located with the Microbiome Discovery & Development Congress

2018 Speakers Include:

- Anna Maroney
  - AbbVie

- Thorsten Thormann
  - LEO Pharma

- Magnus Walter
  - Eli Lilly

- Vivek K Vishnudas
  - Berg

- Hubert Haag
  - Sanofi

- Dmitry Samarsky
  - Silence Therapeutics

Day 1: Chemical Computing Group Pre-Congress Workshop

Complimentary | 6th June | Berlin

**Computational Ligand and Structure-Based Drug Design**

Complimentary Live Webinars:

- Wednesday 21st March at 10.30am GMT/ 11.30 CET
  - Application Of Acoustics In Mass Spectrometry, An Alternative Approach For Generation Of High Content Data – hosted by Jonathan Wingfield, Principal Scientist, AstraZeneca

- Thursday 22nd March 2018 at 1.30pm GMT/ 2.30pm CET
  - Computer-Guided Discovery Of Bioactive Natural Products – hosted by Johannes Kirchmair, Professor of Applied Bioinformatics, Center for Bioinformatics, University of Hamburg
Meet Senior Decision Makers: Over 250 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event.

Discover New Solutions
Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

- RNAscreening
- Modelling and Simulation
- Library Optimisation
- DNA Coded Libraries
- Structure Based Drug Discovery
- Computational Chemistry
- Target Validation
- Inhibitor Discovery
- Phenotypic Screening
- Lead Optimisation
- Contract Drug Discovery Research
- Imaging Technology
- Chemistry Disease Models
- High Throughput Cytometry
- Assay Development
- ADME
- Automation
- Drug Design
- Data Analysis/ Management

2018 Speakers Include:
- Magnus Walter, Chief Scientific Officer Global Neurodegeneration, Eli Lilly
- Petr Vachal, Vice President Discovery Chemistry, MSD
- Philip Tagari, Vice President Research, Amgen
- Anna Maroney, Vice President, Head of Alliance Management, AbbVie
- Thorsten Thormann, Senior Vice President New Product Discovery, LEO Pharma
- Juergen Gamer, Vice President Business Development, Apogenix
- Yolanda Chong, Vice President Biology, Recursion Pharmaceuticals
- Nils Jakob Vest Hansen, Chief Executive Officer, Vipergen ApS
- Alexander Alanine, Chief Operating Officer, Bactevo
- Vivek K Vishnudas, Chief Technology Officer, Berg
- Thomas Franch, Chief Scientific Officer, Merus
- Dmitry Samarsky, Chief Scientific Officer, Silence Therapeutics
- Mark Throsby, Chief Scientific Officer, Merus BV
- Christel Menet, Chief Scientific Officer, Confo Therapeutics
- Hubert Haag, Director Lead Discovery – Global Sourcing & External Business Opportunities, Sanofi
- Jag Heer, Director of Medicinal Chemistry, UCB
- Mike Hann, GSK Senior Fellow & Director, Drug Design & Selection, GlaxoSmithKline
- Rob Howes, Director Reagents and Assay Development, Discovery Sciences, AstraZeneca
- Ray Kemper, Director Discovery and Investigative Toxicology, Vertex
- Joel Klappenbach, Director, Applied Genomics, MSD
- Malin Lemurell, Director of Medicinal Chemistry, AstraZeneca
- Jing Li, Director of Pharmacology, Screening and Triage, MSD
- Carl Petersson, Scientific Director Drug Disposition, Merck KGaA
- Wei-Sheng Huang, Director of Discovery Chemistry, Takeda
- Daniel Zwilling, Director of CNS Discovery, Circuit Therapeutics
- Stefan Geschwindner, Associate Director, Head of Biophysics, AstraZeneca
- Julie Selkirk, Associate Director Biology, Celgene
- Georgios Stamatas, Research Associate Director, Johnson & Johnson
- Nathan Brown, Head Cheminformatics, BenevolentAI
- Jose Duca, Head, Computer-Aided Drug Discovery, Novartis
- Christoph Dumelin, Laboratory Head, Novartis
- Florian Fuchs, CBT Screening Sciences, Head Cellular Assays, Novartis
- Tobias Gabriel, Head External Drug Discovery, Novartis
- Anish Konkar, Cluster Head, GI Endocrinology & Obesity, Sanofi-Aventis
- Amaury Fernández Montalván, Laboratory Head, Bayer
- Gerhard Hessler, Head of Synthetic Molecular Design, Sanofi
- Joerg Knaebel, Head of CoLaborator, Berlin & Technology Scouting, Bayer
- Ulrich Schopper, Head Integrated Target and Lead Discovery, Novartis
- Franz Schuler, Head Drug Disposition and Safety, Pharmaceutical Sciences, Roche
- Alan Whitmore, Head of Discovery Biology, e-Therapeutics
- Lutz Mueller, Distinguished Scientist, F. Hoffmann-La Roche
- Phil Cox, Senior Principal Research Scientist, FBDD Chemistry Group Leader, AbbVie
- Ye Che, Senior Principal Scientist, Pfizer
- Hasane Ratni, Senior Principal Scientist, F. Hoffmann-La Roche
- Jörg Bentzien, Principal Scientist, FORMA Therapeutics
- Peter Ellmark, Principal Scientist, Alligator Bioscience
- Mike Morrison, Principal Scientist, Epizyme
- Jonathan Wingfield, Principal Scientist, AstraZeneca

For more information please contact marketing@oxfordglobal.co.uk
2018 Speakers Continued:
- Dan Blat, Senior Scientist Preclinical Biology, Immunocore Ltd.
- Iulia Diaconu, Senior Scientist 1, Bluebird Bio
- Anthony Donofrio, Senior Scientist HTE and Lead Discovery Capabilities, MSD
- Vineet Pande, Senior Scientist Computational Chemistry, Janssen
- Davide Gianni, Team Leader Discovery Biology, AstraZeneca
- Steve Andrews, Head of Chemistry, Cambridge Drug Discovery Institute
- Paul Andrews, Director of Operations, National Phenotypic Screening Centre, University of Dundee
- Rod Hubbard, Senior Fellow and Professor, Vernalis and University of York
- Ernesto Freire, Henry Walters Professor, Johns Hopkins University
- Jonathan Hall, Professor, ETH Zurich
- Magnus Ingelman-Sundberg, Professor, Karolinska Institutet
- Johannes Kirchmair, Professor of Applied Bioinformatics, University of Hamburg
- Richard Meehan, Professor, Edinburgh University
- Kristian Stremgaard, Professor, Director, University of Copenhagen
- Paul Brennan, Associate Professor, Medicinal Chemistry, University of Oxford
- Olivia Rossanese, Head of Biology and Reader, The Institute of Cancer Research
- Olivier Sperandio, Group Leader, Head of the Ippi-DB Initiative, Institute Pasteur
- Fredrik Wermeling, Assistant Professor, Karolinska Institutet

Sponsor Speakers Include:
- Saman Honarnejad, Senior Scientist, Pivot Park Screening Centre

2018 Silver Sponsor:

2018 Bronze Sponsors Include:

2018 Event Sponsors Include:

If you’re on Twitter, make sure to follow us @drugdiscovery1 and join the Congress conversation on #DDSummit17

For booking details & registration fees please refer to the last page or visit: http://www.drugdiscovery-summit1.com/marketing
2018 Event Sponsors Continued:

Chemical Computing Group Complimentary Pre-Congress Workshop - Computational Ligand and Structure-Based Drug Design

Sponsored by:

Date: June 6th 2018
Venue: Hotel Palace, Budapesterstr. 45, 10787 Berlin, Germany

Aim of the workshop:
To aid the progression of drug design and discovery projects computationally, with or without protein-ligand structural knowledge.

Workshop Summary:
Computational methods for aiding drug discovery are now widely available and applied in situations where there is the presence (Structure-Based Drug Design) or absence (Ligand-Based Drug Design) of crystal structure information about the bound states of active molecules with their targets. The workshop will illustrate a range of computational techniques through demonstration using the MOE software. Trial copies of MOE can be provided by contacting info@chemcomp.com.

Workshop Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-13:30</td>
<td>Registration and Lunch</td>
</tr>
</tbody>
</table>
| 13:30-15:00   | Ligand-Based Drug Design and SAR Analysis
               | R-Group Profiles and Analysis / MOEsaic / MMP     |
               | Analysis / Descriptor Calculations / Conformational|
               | Searching / Molecular Alignments / Pharmacophore   |
               | Modeling and Searching / Diversity Analysis       |
| 15:00-15:30   | Refreshment Break                                 |
| 15:30-17:00   | Structure-Based Drug Design
<pre><code>           | Pharmacophore Modeling / Docking / Fragment-based|
           | Design / Scaffold Replacement / R-Group Screening |
           | / Project Search / Protein-Ligand Interaction Fingerprint |
</code></pre>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30 – 08.20</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08.20 – 08.25</td>
<td>Oxford Global Welcome Address</td>
<td>Oxford Global Welcome Address</td>
</tr>
<tr>
<td>08.25 – 08.30</td>
<td>Stream Chair Welcome Address</td>
<td>Stream Chair Welcome Address:</td>
</tr>
</tbody>
</table>
| 08.30 – 09.00 | Keynote Address: Establishing And Executing Option-Based Deals That Work For Both Parties | Option based deals are a popular model to distribute risk in a partnership  
  We will explore the benefits and challenges of engaging in this business development model  
  Anna Maroney, Vice President, Head of Alliance Management, AbbVie |
| 08.30 – 09.00 | Keynote Address: Drug Discovery Enabled Through Innovation           | Investment into basic science, informatics, innovation drives better drug discovery in MSD  
  Increase in POS in drug discovery design cycle will be demonstrated with specific project examples  
  Petr Vachal, Vice President Discovery Chemistry, MSD |
| 09.00 – 09.30 | Stream Keynote Address: New Modalities For Treatment Of Cardiovascular And Metabolic Diseases | Today we see immense data being generated from patient material providing a range of exciting novel biological pathways and targets linked to disease. Several of these provide a challenge from a druggability perspective. The strategy we have embarked on to embed New Modalities in or capabilities and some recent examples of how we used New Modalities to find ways of modulating challenging targets or to widen therapeutic window through tissue targeting will be presented.  
  Malin Lemurell, Director of Medicinal Chemistry, AstraZeneca |
| 09.00 – 09.30 | Stream Keynote Address: Next Generation Drug Discovery: T.I.M.E. An Integrated Micro-Droplet Based Platform' | Bactevo has developed a tightly integrated set of game-changing proprietary technologies which radically disrupt current methods of creating new medicines.  
  Our Totally Integrated Medicines Engine (T.I.M.E.) has been devised to address the needs of drug discovery and development scientists. Integrating the latest generation of microfluidics enabling ultra-fast phenotypic assaying, next-generation encoded synthetic libraries, natural products, in vitro profiling and in silico machine learning to create new therapeutics, TIME provides a paradigm shift in the speed, efficiency and quality of drug discovery. Bactevo is applying its TIME platform to create a portfolio of therapeutics for the treatment of diseases involving defects in mitochondrial function, with an internal focus on rare diseases.  
  Alexander Alanine, Chief Operating Officer, Bactevo |
| 09.00 – 09.30 | Stream Keynote Address: Takeda Case Study: Discovery Of Iclusig, Alunbrig And AP32788 | Wei-Sheng Huang, Director of Discovery Chemistry, Takeda |

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Drug Discovery Summit</th>
<th>Discovery Chemistry &amp; Drug Design Congress</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30</td>
<td>Hit Discovery And Optimization Towards Leads To Modulate Trained Immunity</td>
<td>Title To Be Confirmed</td>
</tr>
<tr>
<td></td>
<td>• Center for Open Innovation in LEad Discovery (COILED) is a collaborative drug discovery program focused on epigenetic targets&lt;br&gt;• Modulation of trained innate immunity for treatment of hyper-inflammation and immune deficiency-driven diseases like sepsis and cancer&lt;br&gt;• Parallel approaches such as ultra high-throughput screening (uHTS), scaffold hopping and structure-based drug design are applied to identify small molecule hits (starting points) for further optimization</td>
<td>Solution Provider Presentation&lt;br&gt;For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a></td>
</tr>
<tr>
<td></td>
<td>Saman Honarnejad, Scientist, Pivot Park Screening Centre</td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>Morning Coffee &amp; Refreshments, One to One Meetings x3, Poster Presentation Sessions</td>
<td></td>
</tr>
<tr>
<td>11.20</td>
<td>New Strategies To Enrich Sanofi’s Early Pipeline</td>
<td>Identification Of Therapeutics Using High-Dimensional Phenotypic Signatures</td>
</tr>
<tr>
<td></td>
<td>• Early access to best innovation&lt;br&gt;• Moving from Fishing to Farming&lt;br&gt;• Swapping assets with external partners</td>
<td>Yolanda Chong, Vice President Biology, Recursion Pharmaceuticals&lt;br&gt;Anthony Donofrio, Senior Scientist HTE and Lead Discovery Capabilities, MSD</td>
</tr>
<tr>
<td></td>
<td>Hubert Haag, Director Lead Discovery – Global Sourcing &amp; External Business Opportunities, Sanofi</td>
<td></td>
</tr>
<tr>
<td>11.50</td>
<td>Digital Epidermis: Dynamic Computational Modelling Of Epidermal Physiology And Bioavailability Of Topically Applied Substances</td>
<td>Phenomics, Artificial Intelligence Driven Target Identification And Drug Discovery To Illuminate Novel Patient Biology&lt;br&gt;Computational Approaches Towards Drug Discovery</td>
</tr>
<tr>
<td></td>
<td>• An agent-based dynamic simulation of epidermal physiology in 2D and 3D: development, emerging properties, validation against in vivo experimental data&lt;br&gt;• Topical application of external substances and penetration kinetics using the computational model</td>
<td>Jose Duca, Head, Computer-Aided Drug Discovery, Novartis&lt;br&gt;Vivek K Vishnudas, Chief Technology Officer, Berg</td>
</tr>
<tr>
<td>12.20</td>
<td>Title To Be Confirmed</td>
<td>Title To Be Confirmed</td>
</tr>
<tr>
<td>12.50</td>
<td>Lunch, One to One Meetings x2, Poster Presentation Sessions</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Drug Discovery Summit</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>13.50 – 14.20</td>
<td>Innovative Target Discovery</td>
<td></td>
</tr>
<tr>
<td>Rob Howes,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director Reagents and Assay Development, Discovery Sciences, AstraZeneca</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19th Annual Drug Discovery Summit and 6th Annual Discovery Chemistry and Drug Design</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congress</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1 – 7th June 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.20 – 14.50</td>
<td>The Future Of Drug Discovery With Small Molecules</td>
<td></td>
</tr>
<tr>
<td>Tobias Gabriel, Head External Drug Discovery, Novartis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.50 – 15.20</td>
<td>Title To Be Confirmed</td>
<td></td>
</tr>
<tr>
<td>15.20 – 16.20</td>
<td>Afternoon Coffee &amp; Refreshments, One to One Meetings x 2, Poster Presentation Sessions</td>
<td></td>
</tr>
<tr>
<td>16.20 – 16.50</td>
<td>R&amp;D Scouting And The Berlin CoLaborator: How This Fits Into The Open Innovation Strategy Of Bayer AG</td>
<td></td>
</tr>
<tr>
<td>Joerg Knaeblein, Head of CoLaborator, Berlin &amp; Technology Scouting, Bayer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.50 – 14.20</td>
<td>Drugging the Undrugged: Lead Discovery with a Chemical Biology Mindset</td>
<td></td>
</tr>
<tr>
<td>Ulrich Schopfer, Head Integrated Target and Lead Discovery, Novartis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.20 – 14.50</td>
<td>Application Of Acoustics In Mass Spectrometry, An Alternative Approach For Generation Of High Content Data</td>
<td></td>
</tr>
<tr>
<td>Jonathan Wingfield, Principal Scientist, AstraZeneca</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.50 – 15.20</td>
<td>High Content Screening Is Made Alive</td>
<td></td>
</tr>
<tr>
<td>Florian Fuchs, CBT Screening Sciences, Head Cellular Assays, Novartis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.20 – 16.50</td>
<td>DNA-Encoded Library Technology Platforms: Yoctoreactor And Binder Trap Enrichment</td>
<td></td>
</tr>
<tr>
<td>Nils Jakob Vest Hansen, Chief Executive Officer, Vipergen ApS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For more information please contact marketing@oxfordglobal.co.uk
### 19th Annual Drug Discovery Summit and 6th Annual Discovery Chemistry and Drug Design Congress

**Day 1 – 7th June 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.50–17.20</td>
<td><strong>Disrupting Drug Discovery With Artificial Intelligence</strong>&lt;br&gt;• Only a small fraction of globally generated scientific information is used to make informed decisions&lt;br&gt;• AI can offer a solution to this problem and machine learning technology is changing the way new medicines are designed, discovered and developed&lt;br&gt;• Using AI to augment human intelligence: essential in providing experienced scientists with the tools they need to design better compounds faster</td>
<td>Nathan Brown, Head Cheminformatics, BenevolentAI</td>
</tr>
<tr>
<td>16.50–17.20</td>
<td><strong>The Use Of High-Throughput Cellular Thermal Shift Assay (HT-CETSA) In Drug Discovery</strong>&lt;br&gt;Early drug discovery suffers from a lack of assay technologies that enable detection of target engagement within cells, particularly in a physiologically relevant context. I will present a summary of the applications of this technology in the lead generation process with an emphasis on high-throughput uses. Benchmarking of CETSA technology against established assay formats provide evidence that CETSA can be incorporated into the lead-generation process in a high-throughput manner.</td>
<td>Davide Gianni, Team Leader Discovery Biology, AstraZeneca</td>
</tr>
<tr>
<td>17.20–17.50</td>
<td><strong>Discovery Of Multi-Acting Peptides (Dual / Triple Agonists) For Treating Type 2 Diabetes And Obesity</strong></td>
<td>Anish Konkar, Cluster Head, GI Endocrinology &amp; Obesity, Sanofi-Aventis</td>
</tr>
<tr>
<td>17.20–17.50</td>
<td><strong>The Phenomics Discovery Initiative: Priming The Industrial Drug Discovery Pipeline With The Best Disease-Relevant Biology</strong>&lt;br&gt;• Phenotypic Discovery Science is undergoing a much needed renaissance&lt;br&gt;• The National Phenotypic Screening Centre launched the Phenomics Discovery Initiative (PDi) in 2016&lt;br&gt;• PDi taps into the deep well of disease-relevant biology waiting to be translated into screenable assays&lt;br&gt;• PDi’s approaches and its growing portfolio of complex phenotypic assays will be discussed</td>
<td>Paul Andrews, Director of Operations, National Phenotypic Screening Centre, University of Dundee</td>
</tr>
<tr>
<td>17.50–18.20</td>
<td><strong>Covalent Inhibitors As An Approach For Challenging Targets</strong>&lt;br&gt;• Targeted covalent inhibitors exhibit slow target offset, increased binding efficiency and potency, enhanced selectivity, reduced propensity for targeted-based drug resistance and prolonged pharmacodynamics effects&lt;br&gt;• Computational reactivity assessment of diverse electrophilic warheads to different biological nucleophiles help prioritize the design of covalent drugs</td>
<td>Ye Che, Senior Principal Scientist, Pfizer</td>
</tr>
<tr>
<td>18.20</td>
<td><strong>Networking Drink and End of Day One</strong></td>
<td></td>
</tr>
<tr>
<td>19.30</td>
<td><strong>Congress Dinner</strong></td>
<td></td>
</tr>
</tbody>
</table>

For more information please contact [marketing@oxfordglobal.co.uk](mailto:marketing@oxfordglobal.co.uk)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 07.30 – 08.00 | Breakfast Think Tank Roundtable Discussions | Topic 1: New Modalities in Drug Discovery  
Moderator: Invitation to: Malin Lemurell, Director of Medicinal Chemistry, AstraZeneca  
Topic 2: Genome Based Drug Discovery  
Moderator: CONFIRMED: Jing Li, Director of Pharmacology, Screening and Triage, MSD  
Topic 3: Phenotypic Approaches For Lead Generation  
Moderator: Invitation to: Ulrich Schopfer, Head Integrated Target and Lead Discovery, Novartis  
Topic 4: Broadening The Chemical Space Of DNA Encoded Libraries  
Moderator: Invitation to: Thomas Franch, Chief Scientific Officer, Nuevolution  
Topic 5: Open Innovation And Outsourcing In Drug Discovery  
Moderator: Invitation to: Anna Maroney, Vice President, Head of Alliance Management, AbbVie  
Topic 6: Protein-Protein Interactions – Inhibition, Modulation And Stabilisation  
Moderator: Invitation to: Thorsten Thormann, Senior Vice President New Product Discovery, LEO Pharma |
<p>| 08.00 – 08.30 | Keynote Address: Drug Discovery Approaches To Protein Misfolding And Aggregation Diseases | Magnus Walter, Chief Scientific Officer Global Neurodegeneration, Eli Lilly |
| 08.30 – 09.00 | Solution Provider Presentation | For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a> |
| 09.00 – 09.30 | Solution Provider Presentation | For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a> |
| 09.30 – 10.00 | Solution Provider Presentation | For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a> |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Drug Discovery Summit</th>
<th>Discovery Chemistry &amp; Drug Design Congress</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00 – 11.20</td>
<td>Morning Coffee &amp; Refreshments, Exhibition &amp; Poster Presentation Session, One To One Meetings x4</td>
<td></td>
</tr>
<tr>
<td>11.20 – 11.50</td>
<td><strong>TNF Superfamily Receptor Modulators – Innovative Immuno-oncology Therapeutics</strong></td>
<td><strong>Early Dose Predictions - PKPD Relationships Impacting Medicinal Chemistry</strong></td>
</tr>
<tr>
<td></td>
<td>Apogenix is a clinical stage company targeting proteins of the TNF SF (Tumor Necrosis Factor Super Family)</td>
<td>• Dose predictions versus single parameter driven optimization</td>
</tr>
<tr>
<td></td>
<td>Members of the TNF receptor/ligand family are key modulators of the immune response and attractive targets in immuno-oncology</td>
<td>• Consequences of different PKPD scenarios on optimization endpoints</td>
</tr>
<tr>
<td></td>
<td>Apogenix’ TNF SF modulators are ideal candidates for combination with other IO approaches such as cancer vaccines, cell therapies or checkpoint inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Juergen Gamer, Vice President Business Development, Apogenix</td>
<td>Carl Petersson, Scientific Director Drug Disposition, Merck KGaA</td>
</tr>
<tr>
<td>11.50 – 12.20</td>
<td><strong>A Novel Drug Target Discovery Pipeline For CNS Diseases – Using In Vivo Optogenetics To Identify And Validate Specific Novel Drugable Targets</strong></td>
<td><strong>ADMET Strategies In Drug Discovery</strong></td>
</tr>
<tr>
<td></td>
<td>Identifying specific drugable targets in the CNS is essential for the development of the next generation of drugs and therapies for neurological and psychiatric diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>In vivo optogenetics enables us to activate or deactivate neurons in the brain to model disease states</td>
<td></td>
</tr>
<tr>
<td></td>
<td>In vivo optogenetics offers an opportunity to functionally dissect the neural circuitry in the brain to characterize select neuron populations in behavior</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The molecular characterization of these unique neuronal populations on a single cell basis enables the identification of novel drugable molecular targets that are unique or highly enriched in those neurons</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daniel Zwilling, Director of CNS Discovery, Circuit Therapeutics</td>
<td>Franz Schuler, Head Drug Disposition and Safety, Pharmaceutical Sciences, Roche</td>
</tr>
<tr>
<td>12.20 – 12.50</td>
<td><strong>Targeting Proteostasis With Therapies For Neurodegeneration</strong></td>
<td><strong>Interrogating Histone Methyltransferases By Small Molecule Inhibition</strong></td>
</tr>
<tr>
<td></td>
<td>Steve Andrews, Head of Chemistry, Cambridge Drug Discovery Institute</td>
<td>• Fusion proteins containing HMTs that result from translocations have been linked to several types of cancers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Current literature is devoid of validated, chemical matter for this particular class of HMTs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Validated chemical matter (X-ray, SPR) will be presented on this class of HMTs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mike Morrison, Principal Scientist, Epizyme</td>
</tr>
<tr>
<td>12.50 – 14.00</td>
<td><strong>Lunch, One to One Meetings, Poster Presentations</strong></td>
<td></td>
</tr>
<tr>
<td>Drug Discovery Summit</td>
<td>Discovery Chemistry &amp; Drug Design Congress</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>14.00 – 14.30</strong></td>
<td><strong>14.00 – 14.30</strong></td>
<td></td>
</tr>
<tr>
<td>Bi-Specific T-cell Engagers (BiTEs) – A Powerful Therapeutic Platform For Immuno-Therapy</td>
<td>Thermodynamic-Based Selection And Optimization Of Lead Compounds</td>
<td></td>
</tr>
<tr>
<td>Philip Tagari, Vice President Research, Amgen</td>
<td>Ernesto Freire, Henry Walters Professor, Johns Hopkins University</td>
<td></td>
</tr>
<tr>
<td>The architecture of BiTEs</td>
<td>How can we rapidly identify high quality compounds?</td>
<td></td>
</tr>
<tr>
<td>Directing activated T-cells to tumors</td>
<td>Which compounds achieve higher affinity and superior selectivity?</td>
<td></td>
</tr>
<tr>
<td>Clinical experiences in liquid and solid tumors</td>
<td>What are the best strategies to optimize lead compounds?</td>
<td></td>
</tr>
<tr>
<td>Future directions</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14.30 – 15.00</strong></td>
<td><strong>14.00 – 14.30</strong></td>
<td></td>
</tr>
<tr>
<td>Ozanimod: A Novel Sphingosine 1 Phosphate Receptor Modulator For The Treatment Of Relapsing And Remitting Multiple Sclerosis</td>
<td>Advanced GalNAc-siRNA Platform And Its Therapeutic Applications</td>
<td></td>
</tr>
<tr>
<td>Julie Selkirk, Associate Director Biology, Celgene</td>
<td>siRNA harness natural mechanisms to effectively and specifically silence virtually any gene in the cell</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Structure, properties and delivery of the GalNAc-siRNA gene silencing drugs to hepatocytes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapeutic pipeline and specific programs based of the GalNAc-siRNA technological platform</td>
<td></td>
</tr>
<tr>
<td><strong>15.00 – 15.15</strong></td>
<td><strong>15.00 – 15.15</strong></td>
<td></td>
</tr>
<tr>
<td>Afternoon Coffee &amp; Refreshments, One To One Meetings x4, Poster Presentation Session</td>
<td>Design And Validation Of Tricyclic Allosteric Modulators Of TNF Alpha</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TNF alpha is a cell signalling protein involved in numerous autoimmune disorders. Antibody biologics that bind to TNF alpha have for some time demonstrated the clinical utility of anti-TNF therapy. Despite the clear clinical benefit demonstrated by TNF alpha inhibition, to date no small molecule inhibitor of TNF alpha has entered clinical development. The discovery and development of small molecule inhibitors of TNF alpha has therefore long been considered one of the holy grails of drug discovery. The design and validation of tricyclic modulators of TNF alpha will be discussed. We will show how computational methods and a metabolite identification and isolation platform were useful elements in the optimisation process. The resulting chiral tricyclic compounds have advantageous pharmacokinetic and physicochemical properties.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jag Heer, Director of Medicinal Chemistry, UCB</td>
<td></td>
</tr>
</tbody>
</table>

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Drug Discovery Summit</th>
<th>Discovery Chemistry &amp; Drug Design Congress</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.15 – 15.45</td>
<td><strong>Using Network Driven Drug Discovery To Address T-Cell Exhaustion</strong>&lt;br&gt;Alan Whitmore, Head of Discovery Biology, e-Therapeutics&lt;br&gt;Genome Editing And Drug Discovery&lt;br&gt;Joel Klappenbach, Director, Applied Genomics, MSD&lt;br&gt;SMN2 Splicing Modifier For The Treatment Of SMA - A Fascinating Drug Discovery Journey&lt;br&gt;• Biology approach&lt;br&gt;• First hits&lt;br&gt;• Compounds properties&lt;br&gt;• Optimisation&lt;br&gt;Hasane Ratni, Senior Principal Scientist, F. Hoffmann-La Roche</td>
<td>Safety Optimization Of Small Molecule SMN2 Splice Modifiers For Therapeutic Use In SMA Rare Disease&lt;br&gt;• Pharmacology and safety optimization of RNA splice modifiers&lt;br&gt;• Primary and secondary targets&lt;br&gt;• Therapeutic window&lt;br&gt;Lutz Mueller, Expert Toxicology Project Leader, F. Hoffmann-La Roche</td>
</tr>
<tr>
<td>15.45 – 16.15</td>
<td><strong>Drug Target Kinetics In Drug Discovery</strong>&lt;br&gt;Amaury Fernández Montalván, Laboratory Head, Bayer&lt;br&gt;Employing The CRISPR/Cas9 System In Pre-Clinical Testing Of T Cell Receptor-Based Bispecific Drug Candidates&lt;br&gt;• Overview of the ImmTAC platform: TCR-based bispecific biologics for cancer immunotherapy&lt;br&gt;• The unique requisites when deleting/editing HLA-presented peptides in cell lines&lt;br&gt;• Utilising gene edited cells in pre-clinical screening of TCR-based biologic drugs&lt;br&gt;• Our current yet ever changing CRISPR workflow&lt;br&gt;Dan Blat, Senior Scientist Preclinical Biology, Immunocore Ltd.</td>
<td>Safety Optimization Of Small Molecule SMN2 Splice Modifiers For Therapeutic Use In SMA Rare Disease&lt;br&gt;• Pharmacology and safety optimization of RNA splice modifiers&lt;br&gt;• Primary and secondary targets&lt;br&gt;• Therapeutic window&lt;br&gt;Lutz Mueller, Expert Toxicology Project Leader, F. Hoffmann-La Roche</td>
</tr>
<tr>
<td>16.15 – 16.45</td>
<td><strong>ATOR-1017 - A Tumor Directed Fcγ-Receptor Cross Linking Dependent 4-1BB Agonistic Antibody</strong>&lt;br&gt;ATOR-1017 is an IgG4 antibody binding to the co-stimulatory receptor 4-1BB with a unique functional profile compared to the two 4-1BB antibodies currently in clinical development. The functional activity depends on cross-linking mediated by Fcγ receptors, which directs the immune activation to tumors where 4-1BB as well as certain Fcγ receptors are highly expressed. This reduce the risk of inducing systemic immune activation and liver toxicity, and ATOR-1017 has the potential to be a best-in-class 4-1BB antibody in terms of risk-benefit profile. ATOR-1017 is currently in preclinical development phase and initiation of clinical studies are planned for 2019.&lt;br&gt;Peter Ellmark, Principal Scientist, Alligator Bioscience</td>
<td>Kinase Crystal Miner: An Approach To Repurposing 3D Hinge Binding Fragments And Its Application Towards Hit Finding Libraries And Structure Based Drug Design Of Kinase Inhibitors&lt;br&gt;• Kinase Crystal Miner generates a database of 3D hinge binding fragments by extracting all available 3D information from in-house and public protein kinase x-ray structures&lt;br&gt;• This database can be used to construct hit finding libraries for kinase screens and to identify new kinase scaffolds&lt;br&gt;• The application of Kinase Crystal Miner in drug design is demonstrated on an example for a novel Bruton Tyrosine Kinase inhibitor&lt;br&gt;Jörg Bentzien, Principal Scientist, FORMA Therapeutics</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker/Institution</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>16.45 – 17.15</td>
<td>T Cells As Platforms For Immune-Therapy</td>
<td>Iulia Diaconu, Senior Scientist I, Bluebird Bio</td>
</tr>
<tr>
<td></td>
<td>• Enhanced manufacturing process for improved T cell function</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Gene edited T cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Novel synthetic biology approaches</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel 3D Hepatics In Vitro System For Studying Liver Disease And Chronic Drug Toxicity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatic in vitro systems should be able to provide a cellular</td>
<td></td>
</tr>
<tr>
<td></td>
<td>phenotype similar to the situation in vivo in man. In recent years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>several 3D models mimicking appropriate liver functions have</td>
<td></td>
</tr>
<tr>
<td></td>
<td>been presented. Using a model of 3D PHH spheroids we observed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>that drug metabolism was preserved for several weeks of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cultivation and that transcriptomic, proteomic and metabolomics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>analyses revealed similar phenotype as in freshly isolated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hepatocytes. In addition using this 3D spheroid systems we have</td>
<td></td>
</tr>
<tr>
<td></td>
<td>been able to mimic different liver disease like NAFLD, NASH and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fibrosis and found the system suitable for evaluation of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mechanisms behind and for identification of drug candidates. In</td>
<td></td>
</tr>
<tr>
<td></td>
<td>the lecture recent results describing the properties and usefulness</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of the system will be presented.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magnus Ingelman-Sundberg, Professor, Karolinska Institutet</td>
<td></td>
</tr>
<tr>
<td>17.15 – 17.45</td>
<td>Targeting Protein-Protein Interactions Of Receptor Complexes</td>
<td>Kristian Strømgaard, Professor, Director, University of Copenhagen</td>
</tr>
<tr>
<td></td>
<td>Characterising RNA-Ligand/RBP Interactions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Johann Kirchmair, Professor of Applied Bioinformatics, University of Hamburg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Computer-Guided Discovery Of Bioactive Natural Products</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Coverage of the chemical space by known and by</td>
<td></td>
</tr>
<tr>
<td></td>
<td>readily purchasable natural products</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Virtual screening for the identification of bioactive natural products</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• In silico prediction of the bioactivity spectra and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>metabolic properties of natural products</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Johannes Kirchmair, Professor of Applied Bioinformatics, University of Hamburg</td>
<td></td>
</tr>
<tr>
<td>17.45 – 18.15</td>
<td>Validating New Targets For Cancer Drug Discovery</td>
<td>Olivia Rossanese, Head of Biology and Reader, The Institute of Cancer Research</td>
</tr>
<tr>
<td></td>
<td>From Fragments To Chemical Probes For Epigenetic Targets</td>
<td>Paul Brennan, Associate Professor, Medicinal Chemistry, University of Oxford</td>
</tr>
<tr>
<td></td>
<td>• Fragment based drug discovery using crystallographic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fragment screening</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Chemical probes in target discovery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olivier Sperandio, Group Leader, Head of the Ippi-DB Initiative, Institute Pasteur</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stabilisation Of Protein–Protein Interaction Complexes Through Small Molecules</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enabling Drug Discovery For Challenging Targets</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Establishing feasibility – solving problems in protein</td>
<td></td>
</tr>
<tr>
<td></td>
<td>production and assays</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Generating structural insight when x-ray crystallography is</td>
<td></td>
</tr>
<tr>
<td></td>
<td>tough</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Illustrated with recent work on Mcl-1 and Bcl-2 (both now in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase I trials)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rod Hubbard, Senior Fellow and Professor, Vernalis and University of York</td>
<td></td>
</tr>
</tbody>
</table>
### Innovation in Genome and Cell Based Drug Discovery, Screening, Imaging & Target Discovery

<table>
<thead>
<tr>
<th>18.15 – 18.45</th>
<th>Custom CRISPR Screens Targeting Subsets Of Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Smaller custom CRISPR screens can be a feasible approach for rapid discovery</td>
</tr>
<tr>
<td></td>
<td>• The Green Listed software can be used to facilitate setting up such screens</td>
</tr>
<tr>
<td></td>
<td>• Challenges designing screens most often relates to finding a good and relevant readout, as well as optimizing the delivery of construct into the cells of interest</td>
</tr>
</tbody>
</table>

Fredrik Wermeling, Assistant Professor, Karolinska Institutet

| 18.45 | End of Conference |
Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates

Title: ___________________________ Forename: ___________________________ Surname: ___________________________
Job Title: ___________________________
Company/Organisation: ____________________________________________________________
Email: ___________________________
Address: ___________________________
Postcode: ___________________________
Country: ___________________________
Direct Telephone: ___________________________ Direct Fax: ___________________________
Signature: ___________________________
Date: ___________________________

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

Delegate Booking Fee
The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an Invoice. This charge will not be applied to payments settled online.

Poster Presentations
Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size.

Cancellation and Curtailment
Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

Between 6 and 3 months prior: 35% cancellation fee / 65% refund
Between 3 and 6 months prior: 75% cancellation fee / 25% refund
Less than 3 months prior to the event: Full cancellation fee / No refund

Data Protection
The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein.

Miscellaneous
This Agreement may not be transferred or assigned by either the Delegate or the Delegates’ Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to the Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded. For promotional purposes, there may be professional photography and video production taking place during the conference. Delegates who do not wish to be filmed or recorded should advise the organisers by email to operations@oxfordglobal.co.uk, prior to the event.

I agree to the above Terms and Conditions

Delegate Booking Fee
- Congress: £899
- 1 day pass: £599
- Day 1: £320
- Day 2: £520

Academic Delegates
- Congress: £520
- 1 day pass: £320
- Day 1: £1750
- Day 2: £999

Vendor Delegates
- Congress Only: £1750
- 1 day pass: £999
- Day 1: £999
- Day 2: £520

Poster Presentation: £250

PROMOTIONAL LITERATURE DISTRIBUTION
- Distribution of your company’s promotional literature to all conference attendees: £999

I cannot attend but would like to purchase access to the following:
- Access to the online conference presentations: £499

How to Pay

Number of delegates:
- Industry del(s)  
- Academic del(s)  
- Vendor del(s)

Special Offer: 3 for 2
Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD:  
- Visa  
- Mastercard  
- Maestro  
- Amex

Credit Card Number:

Valid from: ___________________________
Expriy Date: ___________________________
Security code: ___________________________

Cardholders name:
Signature: ___________________________
Date: ___________________________

PLEASE INVOICE ME:

Invoice Address (if different from above): ___________________________

*Please note there is a €65 handling charge for payment via invoice